MY137020A - Diazabicyclic central nervous system active agents - Google Patents

Diazabicyclic central nervous system active agents

Info

Publication number
MY137020A
MY137020A MYPI20011984A MYPI20011984A MY137020A MY 137020 A MY137020 A MY 137020A MY PI20011984 A MYPI20011984 A MY PI20011984A MY PI20011984 A MYPI20011984 A MY PI20011984A MY 137020 A MY137020 A MY 137020A
Authority
MY
Malaysia
Prior art keywords
nervous system
active agents
central nervous
system active
diazabicyclic
Prior art date
Application number
MYPI20011984A
Other languages
English (en)
Inventor
Michael R Schrimpf
Karin R Tietje
Richard B Toupence
Jianguo Ji
Anwer Basha
William H Bunnelle
Jerome F Daanen
Jennifer Mary Pace
Kevin B Sippy
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MY137020A publication Critical patent/MY137020A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20011984A 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents MY137020A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
MY137020A true MY137020A (en) 2008-12-31

Family

ID=27072208

Family Applications (3)

Application Number Title Priority Date Filing Date
MYPI20011984A MY137020A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20055633A MY145722A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20094589A MY168244A (en) 2000-04-27 2005-03-07 Polyester polymer particles having a small surface to center molecular weight gradient

Family Applications After (2)

Application Number Title Priority Date Filing Date
MYPI20055633A MY145722A (en) 2000-04-27 2001-04-26 Diazabicyclic central nervous system active agents
MYPI20094589A MY168244A (en) 2000-04-27 2005-03-07 Polyester polymer particles having a small surface to center molecular weight gradient

Country Status (22)

Country Link
EP (3) EP1284976A2 (enExample)
JP (2) JP4981232B2 (enExample)
KR (4) KR100961406B1 (enExample)
CN (3) CN102863441A (enExample)
AR (1) AR030421A1 (enExample)
AU (2) AU6655901A (enExample)
BG (2) BG66151B1 (enExample)
BR (1) BR0107246A (enExample)
CA (2) CA2683045A1 (enExample)
CZ (4) CZ302038B6 (enExample)
HK (1) HK1054375A1 (enExample)
HU (1) HUP0300602A3 (enExample)
IL (3) IL152231A0 (enExample)
MX (1) MXPA02010594A (enExample)
MY (3) MY137020A (enExample)
NO (1) NO324250B1 (enExample)
NZ (1) NZ521734A (enExample)
PE (1) PE20011305A1 (enExample)
PL (2) PL358340A1 (enExample)
SK (2) SK287273B6 (enExample)
TW (4) TWI311137B (enExample)
WO (1) WO2001081347A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
JP5148507B2 (ja) * 2005-12-20 2013-02-20 アストラゼネカ・アクチエボラーグ Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体及びその合成法
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2008118742A1 (en) 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
PA8802501A1 (es) 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
CN101918409A (zh) * 2007-11-21 2010-12-15 雅培制药有限公司 联芳基取代的二氮杂双环烷衍生物
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CN101952276B (zh) 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
RU2492169C2 (ru) 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные 5-аминоциклилметилоксазолидин-2-она
CA2721099C (en) 2008-04-11 2017-04-25 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
KR20110132607A (ko) * 2009-03-24 2011-12-08 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
NZ596137A (en) 2009-05-14 2013-08-30 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
EP2491034B1 (en) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011050202A1 (en) * 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
MX2017005484A (es) 2014-10-31 2017-10-20 Indivior Uk Ltd Compuestos antagonistas del receptor de dopamina d3.
HRP20220642T1 (hr) 2016-03-10 2022-06-24 Janssen Pharmaceutica Nv Postupci za liječenje depresije uporabom antagonista receptora oreksina 2
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
SMT202400265T1 (it) 2018-11-14 2024-07-09 Janssen Pharmaceutica Nv Metodi di sintesi migliorati per realizzare composti eterociclici fusi come modulatori del recettore per l'oressina
WO2020239073A1 (zh) * 2019-05-30 2020-12-03 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
EP4010325A1 (en) 2019-08-07 2022-06-15 Janssen Pharmaceutica NV Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079391T3 (es) 1989-04-17 1996-01-16 Bayer Ag Procedimiento para la obtencion de 2,7-diazabiciclo(3.3.0)octanos.
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
JP3268098B2 (ja) 1992-12-25 2002-03-25 第一製薬株式会社 二環性環状アミン誘導体
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
DK0842178T3 (da) * 1995-07-28 2001-08-06 Abbott Lab Furopyridin, thienopyridin, pyrrolopyridin og beslægtede pyrimidin-, pyridazin- og triazinforbindelser, som er nyttige til regulering af kemisk synaptisk transmission
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
CA2289574C (en) * 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
DK0984966T3 (da) * 1997-05-30 2003-05-05 Neurosearch As 9-azabicyclo[3.3.1]non-2-en derivater, som er cholinerge ligander på nikotin-ACh receptorer
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
AU744539B2 (en) * 1997-10-27 2002-02-28 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
CA2317567A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
JP2003500402A (ja) * 1999-05-21 2003-01-07 アボット・ラボラトリーズ 中枢神経系薬として有用なアミノアザ環のヘテロ環置換体
WO2001044243A2 (en) * 1999-12-14 2001-06-21 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes

Also Published As

Publication number Publication date
CN100430398C (zh) 2008-11-05
NO324250B1 (no) 2007-09-17
TWI311137B (en) 2009-06-21
BG110620A (bg) 2010-07-30
PE20011305A1 (es) 2001-12-31
KR100947188B1 (ko) 2010-03-12
TWI323733B (en) 2010-04-21
CZ20023765A3 (cs) 2003-02-12
IL203035A (en) 2010-12-30
PL358340A1 (en) 2004-08-09
KR100947187B1 (ko) 2010-03-12
PL398491A1 (pl) 2012-06-04
TW200617013A (en) 2006-06-01
HUP0300602A3 (en) 2005-12-28
MY145722A (en) 2012-03-30
KR100899950B1 (ko) 2009-05-28
AU6655901A (en) 2001-11-07
CN1440410A (zh) 2003-09-03
WO2001081347A3 (en) 2002-01-31
NZ521734A (en) 2004-10-29
CZ302072B6 (cs) 2010-09-29
BG66151B1 (bg) 2011-08-31
CA2407094C (en) 2009-11-17
AU2001266559B2 (en) 2005-03-03
SK16812002A3 (sk) 2003-04-01
KR20090013833A (ko) 2009-02-05
WO2001081347A2 (en) 2001-11-01
HUP0300602A2 (hu) 2003-06-28
EP1284976A2 (en) 2003-02-26
HK1054375A1 (zh) 2003-11-28
AU2001266559C1 (en) 2005-11-17
MXPA02010594A (es) 2003-05-14
NO20025107D0 (no) 2002-10-24
BR0107246A (pt) 2002-10-01
CZ302795B6 (cs) 2011-11-16
SK287273B6 (sk) 2010-05-07
JP2003531210A (ja) 2003-10-21
BG107303A (bg) 2003-07-31
EP2298775A1 (en) 2011-03-23
JP2012041349A (ja) 2012-03-01
AR030421A1 (es) 2003-08-20
KR100961406B1 (ko) 2010-06-09
TW201141871A (en) 2011-12-01
EP2295437A1 (en) 2011-03-16
CZ301324B6 (cs) 2010-01-13
JP4981232B2 (ja) 2012-07-18
CZ302038B6 (cs) 2010-09-15
TW200909432A (en) 2009-03-01
IL177316A (en) 2010-06-30
KR20090071654A (ko) 2009-07-01
CA2407094A1 (en) 2001-11-01
SK287658B6 (sk) 2011-05-06
TWI357903B (en) 2012-02-11
NO20025107L (no) 2002-12-19
KR20020093955A (ko) 2002-12-16
MY168244A (en) 2018-10-15
IL177316A0 (en) 2006-12-10
IL152231A0 (en) 2003-05-29
CA2683045A1 (en) 2001-11-01
CN101935322A (zh) 2011-01-05
CN102863441A (zh) 2013-01-09
KR20090121385A (ko) 2009-11-25

Similar Documents

Publication Publication Date Title
TW200617013A (en) Diazabicyclic central nervous system active agents
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
NO20000311D0 (no) Nye forbindelser
IL153297A0 (en) Compounds and compositions for delivering active agents
AU7779900A (en) Trifluoromethyl-substituted spirocyclic ketoenols
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
TR200000197T2 (tr) Yeni bileşimler
BR0114829A (pt) Novos compostos
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
GB2394826A (en) Educational game
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
AU2001266575A1 (en) Chemical compounds
TR199802401T2 (xx) Peptid olmayan G-CSF mimetikleri.
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
CA2408541A1 (en) Treating eczema and/or psoriasis
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
AU9067198A (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
IL142295A0 (en) Use of acylcarnitines as antitumour agents
UY26683A1 (es) Agentes diazabicíclicos activos en el snc
SE0004098D0 (sv) Novel compounds
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof